CMS announces drugs selected for third round of drug price negotiations
The Centers for Medicare & Medicaid Services Jan. 27 announced 15 drugs under Medicare Parts D and B selected for the third round of price negotiations. Negotiations will occur this year and any resulting prices will become effective in 2028. CMS said the selected drugs accounted for nearly $27 billion, or nearly 6%, in total prescription drug spending under Parts D and B between November 2024 and October 2025. Additionally, CMS released a list of the top 50 negotiation-eligible drugs based on combined expenditures under Parts D and B.
Related News Articles
Headline
The Centers for Medicare & Medicaid Services announced in a memo April 21that it is delaying implementation of the Medicare Part D portion of the Better…
Headline
President Trump April 18 signed an executive order to accelerate research into psychedelic drugs for the treatment of serious mental illnesses, calling…
Headline
The U.S. Court of Appeals for the 5th Circuit April 9 affirmed rulings by a Mississippi district court that rejected requests by Novartis and PhRMA to enjoin…
Headline
The White House April 2 issued a proclamation implementing additional tariffs on certain patented pharmaceutical products and ingredients. The order imposes a…
Headline
The Centers for Medicare & Medicaid Services April 2 released a final rule on policy and technical changes to Medicare Advantage, the Medicare Prescription…
Headline
The AHA commented today on the Centers for Medicare & Medicaid Services’ proposed rule on the Global Benchmark for Efficient Drug Pricing Model, or…